Every 10-Q that Pliant Therapeutics, Inc. (PLRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PLRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLRX filings page.
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing integrin-based therapeutics, now primarily focused on its oral solid-tumor candidate PLN-101095 and an integrin-targeted delivery platform. Development of bexotegrast in idiopathic pulmonary fibrosis was discontinued in 2025 after an unfavorable risk‑benefit profile and related restructuring.
For the quarter ended June 30, 2026, Pliant reported a net loss of $22.4 million, about half the $43.3 million loss a year earlier, driven by lower research and development and general and administrative expenses following the 2025 restructuring and program reprioritization. Research and development expense was $16.7 million versus $32.2 million, and general and administrative expense was $7.1 million versus $13.4 million.
As of June 30, 2026, Pliant held $159.6 million in cash, cash equivalents, restricted cash and short-term investments and had no long‑term debt, but an accumulated deficit of $901.8 million. Management believes existing capital will fund operations for at least 12 months and beyond. An at‑the‑market facility allows issuance of up to $50.0 million of common stock, with no sales to date.
Pliant Therapeutics reported a much smaller net loss of $20.0 million for the quarter ended March 31, 2026, compared with $56.2 million a year earlier, as it completed restructuring and shifted focus to oncology. Operating expenses fell sharply, with research and development down to $13.6 million and general and administrative to $8.2 million.
The company ended the quarter with $172.4 million in cash, cash equivalents, restricted cash and short-term investments and no outstanding debt, and believes this will fund operations for at least the next 12 months and beyond. Pliant is now centered on its integrin-based solid tumor program, PLN‑101095, with a Phase 1b FORTIFY trial enrolling and updated Phase 1 data showing anti-tumor activity in combination with pembrolizumab.
Pliant Therapeutics (PLRX) filed its Q3 2025 10-Q, reporting a net loss of $26.3 million for the quarter and $125.8 million year‑to‑date. Operating expenses fell sharply as the company wound down its discontinued IPF program.
Research and development expense decreased to $17.9 million (from $47.8 million a year ago), and general and administrative fell to $10.3 million (from $14.3 million). Cash, cash equivalents and short‑term investments were $243.3 million as of September 30, 2025. Net cash used in operating activities was $110.5 million for the nine months ended September 30, 2025.
The company discontinued bexotegrast in IPF after safety‑related findings and completed a restructuring that reduced its workforce by approximately 45%. In oncology, the Phase 1 trial of PLN‑101095 completed enrollment; data, including higher dose cohorts, are expected by the end of 2025. After quarter‑end, Pliant voluntarily prepaid its Oxford loan for $32.4 million, terminating the facility. Shares outstanding were 61,449,385 as of November 1, 2025.